Autoinflammation: From monogenic syndromes to common skin diseases

Journal of the American Academy of Dermatology

Volumn 68, Issue 5, 2013, Pages 834-853

  Nguyen, Tien V ^a,c   Cowen, Edward W ^b   Leslie, Kieron S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

anakinra; autoinflammation; common dermatoses; inflammasomes; interleukin 1 beta; periodic fevers

Indexed keywords

ADALIMUMAB; ALPHA2B INTERFERON; ANTIRHEUMATIC AGENT; AZITHROMYCIN; CANAKINUMAB; COLCHICINE; CYCLOSPORIN; DAPSONE; ETANERCEPT; ETRETINATE; IMMUNOGLOBULIN; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SALAZOSULFAPYRIDINE; SIMVASTATIN; STEROID; THALIDOMIDE; TOCILIZUMAB; TOLL LIKE RECEPTOR;

ABDOMINAL PAIN; ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADRENAL SUPPRESSION; AUTOINFLAMMATORY DISEASE; AUTOSOMAL DISORDER; BACTERIAL ARTHRITIS; BLAU SYNDROME; CHRONIC ATYPICAL NEUTROPHILIC DERMATITIS WITH LIPODYSTROPHY WITH LIPODYSTROPHY ELEVATED TEMPERATURE SYNDROME; CINCA SYNDROME; CONSTIPATION; DEFICIENCY OF THE INTERLEUKIN 1 RECEPTOR ANTAGONIST; DIARRHEA; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; FLATULENCE; GASTRITIS; HEADACHE; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; HYPERTENSION; INFECTION; INJECTION SITE REACTION; INSOMNIA; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; MYOPATHY; NAUSEA; NEUTROPENIA; NEUTROPHIL; OSTEOPOROSIS; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; PYODERMA GANGRENOSUM; RASH; REVIEW; SAPHO SYNDROME; SCHNITZLER SYNDROME; SIDE EFFECT; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VIRAL UPPER RESPIRATORY TRACT INFECTION; VITILIGO; VOMITING;

AUTOIMMUNE DISEASES; DERMATITIS; HUMANS; INFLAMMASOMES; SYNDROME;

EID: 84876413329     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.11.002     Document Type: Review

References (229)

1. Z. Ye, and J.P. Ting NLR, the nucleotide-binding domain leucine-rich repeat containing gene family Curr Opin Immunol 20 2008 3 9
2. J.P. Ting, R.C. Lovering, E.S. Alnemri, J. Bertin, J.M. Boss, and B.K. Davis The NLR gene family: a standard nomenclature Immunity 28 2008 285 287
3. K. Schroder, and J. Tschopp The inflammasomes Cell 140 2010 821 832
4. M. Keller, A. Ruegg, S. Werner, and H.D. Beer Active caspase-1 is a regulator of unconventional protein secretion Cell 132 2008 818 831
5. R.L. Glaser, and R. Goldbach-Mansky The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies Curr Allergy Asthma Rep 8 2008 288 298
6. C.A. Dinarello, T. Ikejima, S.J. Warner, S.F. Orencole, G. Lonnemann, and J.G. Cannon Interleukin 1 induces interleukin 1, I: induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro J Immunol 139 1987 1902 1910
7. H.J. Lachmann, P. Lowe, S.D. Felix, C. Rordorf, K. Leslie, and S. Madhoo In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes J Exp Med 206 2009 1029 1036
8. R. Zhou, A.S. Yazdi, P. Menu, and J. Tschopp A role for mitochondria in NLRP3 inflammasome activation Nature 469 2011 221 225
9. D.R. Mason, P.L. Beck, and D.A. Muruve Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases J Innate Immun 4 2012 16 30
10. H.M. Doeglas, and E. Bleumink Familial cold urticaria: clinical findings Arch Dermatol 110 1974 382 388
11. B. Stych, and D. Dobrovolny Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives Curr Med Res Opin 24 2008 1577 1582
12. J.R. Yu, and K.S. Leslie Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response Curr Allergy Asthma Rep 11 2011 12 20
13. T. Kubota, and R. Koike Cryopyrin-associated periodic syndromes: background and therapeutics Mod Rheumatol 20 2010 213 221
14. K.S. Leslie, H.J. Lachmann, E. Bruning, J.A. McGrath, A. Bybee, and J.R. Gallimore Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations Arch Dermatol 142 2006 1591 1597
15. G.A. Montealegre Sanchez, and P.J. Hashkes Neurological manifestations of the Mendelian-inherited autoinflammatory syndromes Dev Med Child Neurol 51 2009 420 428
16. T.A. Dowds, J. Masumoto, L. Zhu, N. Inohara, and G. Nunez Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC J Biol Chem 279 2004 21924 21928
17. I. Aksentijevich, M. Nowak, M. Mallah, J.J. Chae, W.T. Watford, and S.R. Hofmann De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases Arthritis Rheum 46 2002 3340 3348
18. H.M. Hoffman, J.L. Mueller, D.H. Broide, A.A. Wanderer, and R.D. Kolodner Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome Nat Genet 29 2001 301 305
19. J. Feldmann, A.M. Prieur, P. Quartier, P. Berquin, S. Certain, and E. Cortis Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes Am J Hum Genet 71 2002 198 203
20. L. Agostini, F. Martinon, K. Burns, M.F. McDermott, P.N. Hawkins, and J. Tschopp NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder Immunity 20 2004 319 325
21. P.N. Hawkins, H.J. Lachmann, E. Aganna, and M.F. McDermott Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra Arthritis Rheum 50 2004 607 612
22. E. Ramos, J.I. Arostegui, S. Campuzano, J. Rius, C. Bousono, and J. Yague Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS) Rheumatology (Oxford) 44 2005 1072 1073
23. C. Boschan, O. Witt, P. Lohse, I. Foeldvari, H. Zappel, and L. Schweigerer Neonatal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment Am J Med Genet A 140 2006 883 886
24. R. Goldbach-Mansky, N.J. Dailey, S.W. Canna, A. Gelabert, J. Jones, and B.I. Rubin Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition N Engl J Med 355 2006 581 592
25. B. Neven, I. Marvillet, C. Terrada, A. Ferster, N. Boddaert, and V. Couloignier Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome Arthritis Rheum 62 2010 258 267
26. A.N. Economides, L.R. Carpenter, J.S. Rudge, V. Wong, E.M. Koehler-Stec, and C. Hartnett Cytokine traps: multi-component, high-affinity blockers of cytokine action Nat Med 9 2003 47 52
27. R. Goldbach-Mansky, S.D. Shroff, M. Wilson, C. Snyder, S. Plehn, and B. Barham A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome Arthritis Rheum 58 2008 2432 2442
28. H.M. Hoffman, M.L. Throne, N.J. Amar, M. Sebai, A.J. Kivitz, and A. Kavanaugh Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies Arthritis Rheum 58 2008 2443 2452
29. H.J. Lachmann, I. Kone-Paut, J.B. Kuemmerle-Deschner, K.S. Leslie, E. Hachulla, and P. Quartier Use of canakinumab in the cryopyrin-associated periodic syndrome N Engl J Med 360 2009 2416 2425
30. N.M. Lindor, T.M. Arsenault, H. Solomon, C.E. Seidman, and M.T. McEvoy A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome Mayo Clin Proc 72 1997 611 615
31. N.G. Shoham, M. Centola, E. Mansfield, K.M. Hull, G. Wood, and C.A. Wise Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway Proc Natl Acad Sci U S A 100 2003 13501 13506
32. E.J. Smith, F. Allantaz, L. Bennett, D. Zhang, X. Gao, and G. Wood Clinical, molecular, and genetic characteristics of PAPA syndrome: a review Curr Genomics 11 2010 519 527
33. A.F. Edrees, D.L. Kaplan, and N.I. Abdou Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) associated with hypogammaglobulinemia and elevated serum tumor necrosis factor-alpha levels J Clin Rheumatol 8 2002 273 275
34. J.C. Jacobs, and E.J. Goetzl "Streaking leukocyte factor," arthritis, and pyoderma gangrenosum Pediatrics 56 1975 570 578
35. M. Brenner, T. Ruzicka, G. Plewig, P. Thomas, and P. Herzer Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra Br J Dermatol 161 2009 1199 1201
36. D.S. Stichweh, M. Punaro, and V. Pascual Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome Pediatr Dermatol 22 2005 262 265
37. E. Cortis, F. De Benedetti, A. Insalaco, S. Cioschi, F. Muratori, and L.E. D'Urbano Abnormal production of tumor necrosis factor (TNF)-alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [published correction appears in J Pediatr 2005;146:193] J Pediatr 145 2004 851 855
38. N.D. Tofteland, and T.S. Shaver Clinical efficacy of etanercept for treatment of PAPA syndrome J Clin Rheumatol 16 2010 244 245
39. M.A. Schellevis, M. Stoffels, E.P. Hoppenreijs, E. Bodar, A. Simon, and J.W. van der Meer Variable expression and treatment of PAPA syndrome Ann Rheum Dis 70 2011 1168 1170
40. G.M. Pastores, V.V. Michels, G.B. Stickler, W.P. Su, A.M. Nelson, and D.A. Bovenmyer Autosomal dominant granulomatous arthritis, uveitis, skin rash, and synovial cysts J Pediatr 117 1990 403 408
41. S.A. Raphael, E.B. Blau, W.H. Zhang, and S.H. Hsu Analysis of a large kindred with Blau syndrome for HLA, autoimmunity, and sarcoidosis Am J Dis Child 147 1993 842 848
42. B. Snyers, and K. Dahan Blau syndrome associated with a CARD15/NOD2 mutation Am J Ophthalmol 142 2006 1089 1092
43. T. Kurokawa, T. Kikuchi, K. Ohta, H. Imai, and N. Yoshimura Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation Ophthalmology 110 2003 2040 2044
44. D. Alonso, G.W. Elgart, and L.A. Schachner Blau syndrome: a new kindred J Am Acad Dermatol 49 2003 299 302
45. J.V. Schaffer, P. Chandra, B.R. Keegan, P. Heller, and H.T. Shin Widespread granulomatous dermatitis of infancy: an early sign of Blau syndrome Arch Dermatol 143 2007 386 391
46. V. Dhondt, S. Hofman, K. Dahan, and H. Beele Leg ulcers: a new symptom of Blau syndrome? Eur J Dermatol 18 2008 635 637
47. J. Stoevesandt, H. Morbach, T.M. Martin, M. Zierhut, H. Girschick, and H. Hamm Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period Pediatr Dermatol 27 2010 69 73
48. X. Wang, H. Kuivaniemi, G. Bonavita, L. Mutkus, U. Mau, and E. Blau CARD15 mutations in familial granulomatosis syndromes: a study of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy Arthritis Rheum 46 2002 3041 3045
49. S.S. Ting, J. Ziegler, and E. Fischer Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions J Pediatr 133 1998 450 452
50. S.K. Saini, and C.D. Rose Liver involvement in familial granulomatous arthritis (Blau syndrome) J Rheumatol 23 1996 396 399
51. M.L. Becker, T.M. Martin, T.M. Doyle, and C.D. Rose Interstitial pneumonitis in Blau syndrome with documented mutation in CARD15 Arthritis Rheum 56 2007 1292 1294
52. H.L. Israel Prognosis of sarcoidosis Ann Intern Med 73 1970 1038 1039
53. C. Miceli-Richard, S. Lesage, M. Rybojad, A.M. Prieur, S. Manouvrier-Hanu, and R. Hafner CARD15 mutations in Blau syndrome Nat Genet 29 2001 19 20
54. T. Hisamatsu, M. Suzuki, H.C. Reinecker, W.J. Nadeau, B.A. McCormick, and D.K. Podolsky CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells Gastroenterology 124 2003 993 1000
55. Y. Ogura, N. Inohara, A. Benito, F.F. Chen, S. Yamaoka, and G. Nunez Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB J Biol Chem 276 2001 4812 4818
56. T.M. Martin, Z. Zhang, P. Kurz, C.D. Rose, H. Chen, and H. Lu The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity Arthritis Rheum 60 2009 611 618
57. J.I. Arostegui, C. Arnal, R. Merino, C. Modesto, M. Antonia Carballo, and P. Moreno NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort Arthritis Rheum 56 2007 3805 3813
58. K. Yasui, M. Yashiro, M. Tsuge, A. Manki, K. Takemoto, and M. Yamamoto Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism Arthritis Rheum 62 2010 250 257
59. N. Milman, C.B. Andersen, A. Hansen, T. van Overeem Hansen, F.C. Nielsen, and H. Fledelius Favorable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation APMIS 114 2006 912 919
60. R. Schmaltz, T. Vogt, and J. Reichrath Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) Dermatoendocrinol 2 2010 26 29
61. K.M. Hull, E. Drewe, I. Aksentijevich, H.K. Singh, K. Wong, and E.M. McDermott The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder Medicine (Baltimore) 81 2002 349 368
62. J.R. Toro, I. Aksentijevich, K. Hull, J. Dean, and D.L. Kastner Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations Arch Dermatol 136 2000 1487 1494
63. M.F. McDermott, I. Aksentijevich, J. Galon, E.M. McDermott, B.W. Ogunkolade, and M. Centola Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes Cell 97 1999 133 144
64. F.C. Kimberley, A.A. Lobito, R.M. Siegel, and G.R. Screaton Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome Arthritis Res Ther 9 2007 217
65. M. Gattorno, M.A. Pelagatti, A. Meini, L. Obici, R. Barcellona, and S. Federici Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome Arthritis Rheum 58 2008 1516 1520
66. P.M. Vaitla, P.M. Radford, P.J. Tighe, R.J. Powell, E.M. McDermott, and I. Todd Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab Arthritis Rheum 63 2011 1151 1155
67. A.A. Jesus, J.B. Oliveira, I. Aksentijevich, E. Fujihira, M.M. Carneiro-Sampaio, and A.J. Duarte TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept Eur J Pediatr 167 2008 1421 1425
68. E. Drewe, E.M. McDermott, and R.J. Powell Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome N Engl J Med 343 2000 1044 1045
69. A.C. Bulua, D.B. Mogul, I. Aksentijevich, H. Singh, D. He, and L. Muenz Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) Arthritis Rheum 64 2012 908 913
70. E. Drewe, E.M. McDermott, P.T. Powell, J.D. Isaacs, and R.J. Powell Prospective study of anti-tumor necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumor necrosis factor receptor superfamily 1A fusion protein, in tumor necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients Rheumatology (Oxford) 42 2003 235 239
71. B. Nedjai, G.A. Hitman, N. Quillinan, R.J. Coughlan, L. Church, and M.F. McDermott Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome Arthritis Rheum 60 2009 619 625
72. J.P. Drenth, B.W. Boom, J. Toonstra, and J.W. Van der Meer Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome: international hyper IgD study group Arch Dermatol 130 1994 59 65
73. J.C. van der Hilst, E.J. Bodar, K.S. Barron, J. Frenkel, J.P. Drenth, and J.W. van der Meer Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome Medicine (Baltimore) 87 2008 301 310
74. B. Bader-Meunier, B. Florkin, J. Sibilia, C. Acquaviva, E. Hachulla, and G. Grateau Mevalonate kinase deficiency: a survey of 50 patients Pediatrics 128 2011 e152 e159
75. B.W. Boom, M.R. Daha, B.J. Vermeer, and J.W. van der Meer IgD immune complex vasculitis in a patient with hyperimmunoglobulinemia D and periodic fever Arch Dermatol 126 1990 1621 1624
76. Milhavet F, Touitou I. Infevers: an online database for autoinflammatory mutations. Copyright 2001-2013. Available at http://fmf.igh.cnrs.fr/ISSAID/ infevers/. Accessed April 5, 2012.
77. S. Normand, B. Massonnet, A. Delwail, L. Favot, L. Cuisset, and G. Grateau Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation Eur Cytokine Netw 20 2009 101 107
78. A. Pontillo, E. Paoluzzi, and S. Crovella The inhibition of mevalonate pathway induces up-regulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency Eur J Hum Genet 18 2010 844 847
79. K. Chen, W. Xu, M. Wilson, B. He, N.W. Miller, and E. Bengten Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils Nat Immunol 10 2009 889 898
80. J.P. Drenth, and J.W. van der Meer Hereditary periodic fever N Engl J Med 345 2001 1748 1757
81. J.P. Drenth, M. van Deuren, J. van der Ven-Jongekrijg, C.G. Schalkwijk, and J.W. van der Meer Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome Blood 85 1995 3586 3593
82. H. Attout, S. Guez, I. Ranaivo, N. Jameerbaccus, and C. Series A patient with hyper-IgD syndrome responding to simvastatin treatment Eur J Intern Med 19 2008 e82 e83
83. E. Demirkaya, M.K. Caglar, H.R. Waterham, R. Topaloglu, and S. Ozen A patient with hyper-IgD syndrome responding to anti-TNF treatment Clin Rheumatol 26 2007 1757 1759
84. A. Simon, E. Drewe, J.W. van der Meer, R.J. Powell, R.I. Kelley, and A.F. Stalenhoef Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome Clin Pharmacol Ther 75 2004 476 483
85. R. Topaloglu, N.A. Ayaz, H.R. Waterham, A. Yuce, F. Gumruk, and O. Sanal Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up Clin Rheumatol 27 2008 1317 1320
86. M. Korppi, M.E. Van Gijn, and K. Antila Hyperimmunoglobulinemia D and periodic fever syndrome in children: review on therapy with biological drugs and case report Acta Paediatr 100 2011 21 25
87. D. Rigante, V. Ansuini, B. Bertoni, A.L. Pugliese, L. Avallone, and G. Federico Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome Rheumatol Int 27 2006 97 100
88. E.J. Bodar, L.M. Kuijk, J.P. Drenth, J.W. van der Meer, A. Simon, and J. Frenkel On-demand anakinra treatment is effective in mevalonate kinase deficiency Ann Rheum Dis 70 2011 2155 2158
89. E.J. Bodar, J.C. van der Hilst, J.P. Drenth, J.W. van der Meer, and A. Simon Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model Neth J Med 63 2005 260 264
90. M. Shohat, and G.J. Halpern Familial Mediterranean fever-a review Genet Med 13 2011 487 498
91. M. Cabral, M. Conde, M.J. Brito, H. Almeida, and J.A. Melo Gomes Protracted febrile myalgia syndrome with Henoch-Schönlein purpura: an atypical presentation of familial Mediterranean fever [in Portuguese] Acta Reumatol Port 36 2011 69 74
92. F. Aydin, C. Ozcelik, I. Akpolat, A.Y. Turanli, and T. Akpolat Erysipelas-like erythema with familial Mediterranean fever J Dermatol 38 2011 513 515
93. E. Azizi, and B.K. Fisher Cutaneous manifestations of familial Mediterranean fever Arch Dermatol 112 1976 364 366
94. R. Satta, L. Obici, G. Merlini, and F. Cottoni Late-onset familial Mediterranean fever: an atypical presentation of dermatologic interest Arch Dermatol 143 2007 1080 1081
95. A. Balbir-Gurman, A.M. Nahir, and Y. Braun-Moscovici Vasculitis in siblings with familial Mediterranean fever: a report of three cases and review of the literature Clin Rheumatol 26 2007 1183 1185
96. B. Lange-Sperandio, K. Mohring, F. Gutzler, and O. Mehls Variable expression of vasculitis in siblings with familial Mediterranean fever Pediatr Nephrol 19 2004 539 543
97. J. ten Oever, and D.R. de Munck Recurrent pleurisy as sole manifestation of familial Mediterranean fever [in Dutch] Ned Tijdschr Geneeskd 152 2008 887 890
98. J.C. Lega, C. Khouatra, V. Cottin, and J.F. Cordier Isolated recurrent pleuritis revealing familial Mediterranean fever in adulthood Respiration 79 2010 508 510
99. K. Okutur, S. Seber, E. Oztekin, C. Bes, and F. Borlu Recurrent pericarditis as the initial manifestation of familial Mediterranean fever Med Sci Monit 14 2008 CS139 CS141
100. K. Senel, M.A. Melikoglu, T. Baykal, M. Melikoglu, A. Erdal, and M. Ugur Protracted febrile myalgia syndrome in familial Mediterranean fever Mod Rheumatol 20 2010 410 412
101. M. Shohat, N. Magal, T. Shohat, X. Chen, T. Dagan, and A. Mimouni Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis Eur J Hum Genet 7 1999 287 292
102. R. Gershoni-Baruch, R. Brik, M. Shinawi, and A. Livneh The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever Eur J Hum Genet 10 2002 145 149
103. M. Solak, H. Yildiz, R. Koken, M. Erdogan, B. Eser, and T. Sen Analysis of familial Mediterranean fever gene mutations in 202 patients with familial Mediterranean fever Genet Test 12 2008 341 344
104. M. Pras Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene Scand J Rheumatol 27 1998 92 97
105. I. Touitou, T. Sarkisian, M. Medlej-Hashim, M. Tunca, A. Livneh, and D. Cattan Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever Arthritis Rheum 56 2007 1706 1712
106. M. Lidar, R. Kedem, P. Langevitz, M. Pras, and A. Livneh Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine J Rheumatol 30 2003 2620 2623
107. R. Gattringer, H. Lagler, K.B. Gattringer, S. Knapp, H. Burgmann, and S. Winkler Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky Eur J Clin Invest 37 2007 912 914
108. R. Belkhir, L. Moulonguet-Doleris, E. Hachulla, J. Prinseau, A. Baglin, and T. Hanslik Treatment of familial Mediterranean fever with anakinra Ann Intern Med 146 2007 825 826
109. L.M. Kuijk, A.M. Govers, J. Frenkel, and W.J. Hofhuis Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra Ann Rheum Dis 66 2007 1545 1546
110. U. Meinzer, P. Quartier, J.F. Alexandra, V. Hentgen, F. Retornaz, and I. Kone-Paut Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature Semin Arthritis Rheum 41 2011 265 271
111. C. Moser, G. Pohl, I. Haslinger, S. Knapp, D. Rowczenio, and T. Russel Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation Nephrol Dial Transplant 24 2009 676 678
112. S.A. Bakkaloglu, T. Aksu, B. Goker, A. Unlusoy, H. Peru, and K. Fidan Sulfasalazine treatment in protracted familial Mediterranean fever arthritis Eur J Pediatr 168 2009 1017 1019
113. E. Seyahi, H. Ozdogan, S. Masatlioglu, and H. Yazici Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient Clin Exp Rheumatol 20 2002 S43 S44
114. E. Seyahi, H. Ozdogan, S. Celik, S. Ugurlu, and H. Yazici Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents Clin Exp Rheumatol 24 2006 S99 S103
115. O. Sakallioglu, A. Duzova, and S. Ozen Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever Clin Exp Rheumatol 24 2006 435 437
116. A. Mor, M.H. Pillinger, M. Kishimoto, A.M. Abeles, and A. Livneh Familial Mediterranean fever successfully treated with etanercept J Clin Rheumatol 13 2007 38 40
117. I. Aksentijevich, S.L. Masters, P.J. Ferguson, P. Dancey, J. Frenkel, and A. van Royen-Kerkhoff An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist N Engl J Med 360 2009 2426 2437
118. A. Torrelo, S. Patel, I. Colmenero, D. Gurbindo, F. Lendinez, and A. Hernandez Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome J Am Acad Dermatol 62 2010 489 495
119. Y. Ramot, T. Czarnowicki, A. Maly, P. Navon-Elkan, and A. Zlotogorski Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome: a case report Pediatr Dermatol 28 2011 538 541
120. Y. Liu, Y. Ramot, A. Torrelo, A.S. Paller, N. Si, and S. Babay Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity Arthritis Rheum 64 2012 895 907
121. T.T. Brown Approach to the human immunodeficiency virus-infected patient with lipodystrophy J Clin Endocrinol Metab 93 2008 2937 2945
122. J.E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, and D. Back HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options J Antimicrob Chemother 62 2008 648 660
123. M.F. Kahn, and M.A. Khan The SAPHO syndrome Baillieres Clin Rheumatol 8 1994 333 362
124. C. Matzaroglou, D. Velissaris, A. Karageorgos, M. Marangos, E. Panagiotopoulos, and M. Karanikolas SAPHO syndrome diagnosis and treatment: report of five cases and review of the literature Open Orthop J 3 2009 100 106
125. A.G. Jurik, and H. Graudal Monarthritis of the manubriosternal joint: a follow-up study Rheumatol Int 7 1987 235 241
126. C.L. Benhamou, A.M. Chamot, and M.F. Kahn Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO): a new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 6 1988 109 112
127. A.M. Chamot, C.L. Benhamou, M.F. Kahn, L. Beraneck, G. Kaplan, and A. Prost Acne-pustulosis-hyperostosis-osteitis syndrome: results of a national survey, 85 cases [in French] Rev Rhum Mal Osteoartic 54 1987 187 196
128. H. Sonozaki, H. Mitsui, Y. Miyanaga, K. Okitsu, M. Igarashi, and Y. Hayashi Clinical features of 53 cases with pustulotic arthro-osteitis Ann Rheum Dis 40 1981 547 553
129. M. Ehrenfeld, Y. Samra, and N. Kaplinsky Acne conglobata and arthritis: report of a case and review of the literature Clin Rheumatol 5 1986 407 409
130. M.F. Kahn, M. Bouvier, E. Palazzo, J.G. Tebib, and F. Colson Sternoclavicular pustulotic osteitis (SAPHO): 20-year interval between skin and bone lesions J Rheumatol 18 1991 1104 1108
131. M. Govoni, M. Colina, A. Massara, and F. Trotta SAPHO syndrome and infections Autoimmun Rev 8 2009 256 259
132. M. Colina, C. Pizzirani, M. Khodeir, S. Falzoni, M. Bruschi, and F. Trotta Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra Rheumatology (Oxford) 49 2010 1416 1418
133. D. Wendling, C. Prati, and F. Aubin Anakinra treatment of SAPHO syndrome: short-term results of an open study Ann Rheum Dis 71 2012 1098 1100
134. K. Ben Abdelghani, D.G. Dran, J.E. Gottenberg, J. Morel, J. Sibilia, and B. Combe Tumor necrosis factor-alpha blockers in SAPHO syndrome J Rheumatol 37 2010 1699 1704
135. B. Bjorksten, K.H. Gustavson, B. Eriksson, A. Lindholm, and S. Nordstrom Chronic recurrent multifocal osteomyelitis and pustulosis palmoplantaris J Pediatr 93 1978 227 231
136. A.C. Patterson, and K. Bentley-Corbett Pustulotic arthroosteitis J Rheumatol 12 1985 611 614
137. P. Berbis, C. Deharo, and Y. Privat Osteite rhumatismale aseptique associee la pustulose palmoplantaire. Interet de la colchicine Rev Rhum Mal Osteoartic 17 1988 1410 1411
138. E. Edlund, U. Johnsson, L. Lidgren, H. Pettersson, G. Sturfelt, and B. Svensson Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis Ann Rheum Dis 47 1988 809 815
139. D. Siegel, J.M. Strosberg, F. Wiese, and J. Chen Acne fulminans with a lytic bone lesion responsive to dapsone J Rheumatol 9 1982 344 346
140. R. Andersson Effective treatment with interferon-alpha in chronic recurrent multifocal osteomyelitis J Interferon Cytokine Res 15 1995 837 838
141. H. Tsubota, A. Kataura, Y. Kukuminato, M. Hamamoto, S. Ohguro, and F. Shido Efficacy of tonsillectomy for improving skin lesions of pustulosis palmaris et plantaris-evaluation of 289 cases at the Department of Otolaryngology of Sapporo Medical University [in Japanese] Nihon Jibiinkoka Gakkai Kaiho 97 1994 1621 1630
142. T. Nakamura, M. Oishi, M. Johno, T. Ono, and M. Honda Serum levels of interleukin 6 in patients with pustulosis palmaris et plantaris J Dermatol 20 1993 763 766
143. E. Tinazzi, A. Puccetti, G. Patuzzo, M. Sorleto, A. Barbieri, and C. Lunardi Schnitzler syndrome, an autoimmune-autoinflammatory syndrome: report of two new cases and review of the literature Autoimmun Rev 10 2011 404 409
144. H.D. de Koning, E.J. Bodar, J.W. van der Meer, and A. Simon Schnitzler syndrome: beyond the case reports; review and follow-up of 94 patients with an emphasis on prognosis and treatment Semin Arthritis Rheum 37 2007 137 148
145. M. Janier, D. Bonvalet, M.F. Blanc, F. Lemarchand, B. Cavelier, and A. Ribrioux Chronic urticaria and macroglobulinemia (Schnitzler's syndrome): report of two cases J Am Acad Dermatol 20 1989 206 211
146. S.S. Berdy, and K.J. Bloch Schnitzler's syndrome: a broader clinical spectrum J Allergy Clin Immunol 87 1991 849 854
147. G. Famularo, A. Barracchini, and G. Minisola Severe thrombophilia with antiphospholipid syndrome and hyperhomocysteinemia in a patient with Schnitzler's syndrome Clin Exp Rheumatol 21 2003 366 368
148. T.H. Westhoff, W. Zidek, L. Uharek, J. Steinhoff-Georgieva, and M. van der Giet Impairment of renal function in Schnitzler's syndrome J Nephrol 19 2006 660 663
149. W. Lim, K.H. Shumak, M. Reis, B. Perez-Ordonez, D. Sauder, and A. Fam Malignant evolution of Schnitzler's syndrome-chronic urticaria and IgM monoclonal gammopathy: report of a new case and review of the literature Leuk Lymphoma 43 2002 181 186
150. J.J. Cream, and D. Porter Urticaria in Waldenstrom's macroglobulinemia J R Soc Med 72 1979 858 859
151. R.M. Pujol, M.A. Barnadas, S. Brunet, and J.M. de Moragas Urticarial dermatosis associated with Waldenstrom's macroglobulinemia J Am Acad Dermatol 20 1989 855 857
152. L. Machet, L. Vaillant, M.C. Machet, M. Reisenleiter, P. Goupille, and G. Lorette Schnitzler's syndrome (urticaria and macroglobulinemia): evolution to Waldenstrom's disease is not uncommon Acta Derm Venereol 76 1996 413
153. B. Welsh, and B. Tate Schnitzler's syndrome: report of a case with progression to Waldenstrom's macroglobulinemia Australas J Dermatol 40 1999 201 203
154. P. Migliorini, I. Del Corso, C. Tommasi, and D. Boraschi Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? Eur Cytokine Netw 20 2009 108 111
155. A. Asahina, N. Sakurai, Y. Suzuki, and K. Narushima Schnitzler's syndrome with prominent neutrophil infiltration misdiagnosed as Sweet's syndrome: a typical example of urticarial neutrophilic dermatosis Clin Exp Dermatol 35 2010 e123 e126
156. C. Pizzirani, S. Falzoni, M. Govoni, R. La Corte, S. Donadei, and F. Di Virgilio Dysfunctional inflammasome in Schnitzler's syndrome Rheumatology (Oxford) 48 2009 1304 1308
157. N. Cascavilla, M. Bisceglia, and G. D'Arena Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial Int J Immunopathol Pharmacol 23 2010 633 636
158. E. Besada, and H. Nossent Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review Clin Rheumatol 29 2010 567 571
159. N. Kluger, S. Riviere, B. Guillot, and D. Bessis Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome Acta Derm Venereol 88 2008 287 288
160. N. Klemmer, P. Lenain, X. Balguerie, and X. Le Loet Effectiveness of anti-IL1 in Schnitzler's syndrome Joint Bone Spine 74 2007 509 510
161. G. Cianchini, L. Colonna, F. Bergamo, C. Angelo, and P. Puddu Efficacy of psoralen-UV-A therapy in 3 cases of Schnitzler syndrome Arch Dermatol 137 2001 1536 1537
162. K. Krause, E. Feist, M. Fiene, T. Kallinich, and M. Maurer Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome J Allergy Clin Immunol 129 2012 848 850
163. V.M. Martinez-Taboada, A. Fontalba, R. Blanco, and J.L. Fernandez-Luna Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al Arthritis Rheum 52 2005 2226 2227
164. N.E. Aikawa, C.A. Silva, E. Bonfa, and J.F. Carvalho Schnitzler's syndrome improvement after anti-TNF-alpha therapy Joint Bone Spine 77 2010 491
165. D. Lipsker, Y. Veran, F. Grunenberger, B. Cribier, E. Heid, and E. Grosshans The Schnitzler syndrome: four new cases and review of the literature Medicine (Baltimore) 80 2001 37 44
166. P. Germain, J. Fach, N. Bui, T. Traissac, X. Delbrel, and M. Le Bras Schnitzler syndrome: a rare cause of systemic urticaria [in French] Rev Med Interne 21 2000 285 289
167. M. Pascual-Lopez, A. Hernandez-Nunez, J. Sanchez-Perez, J. Fernandez-Herrera, and A. Garcia-Diez Schnitzler's syndrome with monoclonal IgG kappa gammopathy: good response to cyclosporin J Eur Acad Dermatol Venereol 16 2002 267 270
168. M. Worm, and G. Kolde Schnitzler's syndrome: successful treatment of two patients using thalidomide Br J Dermatol 148 2003 601 602
169. H.D. de Koning, E.J. Bodar, A. Simon, J.C. van der Hilst, M.G. Netea, and J.W. van der Meer Beneficial response to anakinra and thalidomide in Schnitzler's syndrome Ann Rheum Dis 65 2006 542 544
170. N.E. Schartz, S. Buder, H. Sperl, H. Audring, R. Paus, and B. Tebbe Report of a case of Schnitzler's syndrome treated successfully with interferon alpha 2b Dermatology 205 2002 54 56
171. S. Kuenzli, S. Buchet, and J.H. Saurat Successful treatment of Schnitzler's syndrome with interferon alfa-2b Dermatology 205 2002 74
172. S. Yokota, T. Miyamae, T. Imagawa, N. Iwata, S. Katakura, and M. Mori Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis Mod Rheumatol 14 2004 12 17
173. M. Frosch, and J. Roth New insights in systemic juvenile idiopathic arthritis-from pathophysiology to treatment Rheumatology (Oxford) 47 2008 121 125
174. S. Pay, N. Turkcapar, M. Kalyoncu, I. Simsek, E. Beyan, and I. Ertenli A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis Clin Rheumatol 25 2006 639 644
175. J.B. Ghosh, D. Gupta, and N. Chattopadhyay Systemic onset juvenile idiopathic arthritis-its unusual presentation Indian J Pediatr 75 2008 400 402
176. T.W. Muskardin, and B.A. Binstadt Malar rash in systemic juvenile idiopathic arthritis J Rheumatol 37 2010 2187
177. M. Frosch, D. Metze, D. Foell, T. Vogl, C. Sorg, and C. Sunderkotter Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis Exp Dermatol 14 2005 259 265
178. T. Lequerre, P. Quartier, D. Rosellini, F. Alaoui, M. De Bandt, and O. Mejjad Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France Ann Rheum Dis 67 2008 302 308
179. V. Pascual, F. Allantaz, E. Arce, M. Punaro, and J. Banchereau Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade J Exp Med 201 2005 1479 1486
180. P. Quartier, F. Allantaz, R. Cimaz, P. Pillet, C. Messiaen, and C. Bardin A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial) Ann Rheum Dis 70 2011 747 754
181. S. Weidinger, N. Klopp, L. Rummler, S. Wagenpfeil, N. Novak, and H.J. Baurecht Association of NOD1 polymorphisms with atopic eczema and related phenotypes J Allergy Clin Immunol 116 2005 177 184
182. M. Kabesch, W. Peters, D. Carr, W. Leupold, S.K. Weiland, and E. von Mutius Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations J Allergy Clin Immunol 111 2003 813 817
183. F. Macaluso, M. Nothnagel, Q. Parwez, E. Petrasch-Parwez, F.G. Bechara, and J.T. Epplen Polymorphisms in NACHT-LRR (NLR) genes in atopic dermatitis Exp Dermatol 16 2007 692 698
184. A. Pontillo, L. Brandao, R. Guimaraes, L. Segat, J. Araujo, and S. Crovella Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil Autoimmunity 43 2010 583 589
185. X. Dai, K. Sayama, M. Tohyama, Y. Shirakata, Y. Hanakawa, and S. Tokumaru Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes J Allergy Clin Immunol 127 2011 806 814 e1-4
186. H. Watanabe, O. Gaide, V. Petrilli, F. Martinon, E. Contassot, and S. Roques Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity J Invest Dermatol 127 2007 1956 1963
187. C.L. Barker, M.T. McHale, A.K. Gillies, J. Waller, D.M. Pearce, and J. Osborne The development and characterization of an in vitro model of psoriasis J Invest Dermatol 123 2004 892 901
188. H.D. de Koning, D. Rodijk-Olthuis, I.M. van Vlijmen-Willems, L.A. Joosten, M.G. Netea, and J. Schalkwijk A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: up-regulation of dectin-1 in psoriasis J Invest Dermatol 130 2010 2611 2620
189. Garcia-Rodriguez S, Arias-Santiago S, Perandres-Lopez R, Castellote L, Zumaquero E, Navarro P, et al. Increased gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis. J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2011.04372.x. Published online December 6, 2011.
190. C. Hammerberg, Z. Bata-Csorgo, J.J. Voorhees, and K.D. Cooper IL-1 and IL-1 receptor antagonist regulation during keratinocyte cell cycle and differentiation in normal and psoriatic epidermis Arch Dermatol Res 290 1998 367 374
191. K.S. Anderson, S. Petersson, J. Wong, E. Shubbar, N.N. Lokko, and M. Carlstrom Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris Br J Dermatol 163 2010 1085 1089
192. R. Debets, J.P. Hegmans, P. Croughs, R.J. Troost, J.B. Prins, and R. Benner The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis J Immunol 158 1997 2955 2963
193. M. Kristensen, B. Deleuran, D.J. Eedy, M. Feldmann, S.M. Breathnach, and F.M. Brennan Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin: decreased expression of IRAP in psoriatic lesional epidermis Br J Dermatol 127 1992 305 311
194. N. Jung, M. Hellmann, R. Hoheisel, C. Lehmann, I. Haase, and A. Perniok An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX) Clin Rheumatol 29 2010 1169 1173
195. S. Marrakchi, P. Guigue, B.R. Renshaw, A. Puel, X.Y. Pei, and S. Fraitag Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis N Engl J Med 365 2011 620 628
196. M. Viguier, P. Guigue, C. Pages, A. Smahi, and H. Bachelez Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations Ann Intern Med 153 2010 66 67
197. V. Lutz, and D. Lipsker Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of Hallopeau responsive to the interleukin 1 receptor antagonist anakinra Arch Dermatol 148 2012 297 299
198. C.A. Wise, J.D. Gillum, C.E. Seidman, N.M. Lindor, R. Veile, and S. Bashiardes Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder Hum Mol Genet 11 2002 961 969
199. J.W. Yu, T. Fernandes-Alnemri, P. Datta, J. Wu, C. Juliana, and L. Solorzano Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants Mol Cell 28 2007 214 227
200. A.B. Nesterovitch, M.D. Hoffman, M. Simon, P.A. Petukhov, M.D. Tharp, and T.T. Glant Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum Clin Exp Dermatol 36 2011 889 895
201. Y. Ogura, D.K. Bonen, N. Inohara, D.L. Nicolae, F.F. Chen, and R. Ramos A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease Nature 411 2001 603 606
202. S.E. Girardin, I.G. Boneca, J. Viala, M. Chamaillard, A. Labigne, and G. Thomas Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection J Biol Chem 278 2003 8869 8872
203. J.L. Hsiao, R.J. Antaya, T. Berger, T. Maurer, K. Shinkai, and K.S. Leslie Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review Arch Dermatol 146 2010 1265 1270
204. N.M. Mustafa, and M. Lavizzo Sweet's syndrome in a patient with Crohn's disease: a case report J Med Case Rep 2 2008 221
205. D. Kemmett, D.J. Gawkrodger, G. Wilson, and J.A. Hunter Sweet's syndrome in Crohn's disease BMJ 297 1988 1513 1514
206. A. Delluc, N. Limal, X. Puechal, C. Frances, J.C. Piette, and P. Cacoub Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome Ann Rheum Dis 67 2008 278 279
207. N. Kluger, D. Gil-Bistes, B. Guillot, and D. Bessis Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome Dermatology 222 2011 123 127
208. L.M. Tian, H.F. Xie, T. Yang, Y.H. Hu, J. Li, and W.Z. Wang Association study of tumor necrosis factor receptor type 2 M196R and toll-like receptor 2 Arg753Gln polymorphisms with acne vulgaris in a Chinese Han ethnic group Dermatology 221 2010 276 284
209. K. Szabo, G. Tax, K. Kis, K. Szegedi, D.G. Teodorescu-Brinzeu, and C. Dioszegi Interleukin-1A +4845(G> T) polymorphism is a factor predisposing to acne vulgaris Tissue Antigens 76 2010 411 415
210. M. Shibata, M. Katsuyama, T. Onodera, R. Ehama, J. Hosoi, and H. Tagami Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines J Invest Dermatol 129 2009 375 382
211. M.A. van Steensel, S. Badeloe, V. Winnepenninckx, M. Vreeburg, P.M. Steijlen, and M. van Geel Granulomatous rosacea and Crohn's disease in a patient homozygous for the Crohn-associated NOD2/CARD15 polymorphism R702W Exp Dermatol 17 2008 1057 1058
212. S.L. Moschella Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases Int J Dermatol 46 2007 1287 1291
213. M. Braun-Falco, O. Kovnerystyy, P. Lohse, and T. Ruzicka Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome J Am Acad Dermatol 66 2012 409 415
214. I. Touitou, X. Magne, N. Molinari, A. Navarro, A.L. Quellec, and P. Picco MEFV mutations in Behçet's disease Hum Mutat 16 2000 271 272
215. A. Livneh, I. Aksentijevich, P. Langevitz, Y. Torosyan, N. G-Shoham, and Y. Shinar A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Behçet's disease (FMF-BD) Eur J Hum Genet 9 2001 191 196
216. Z. Amoura, C. Dode, S. Hue, S. Caillat-Zucman, S. Bahram, and M. Delpech Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease Arthritis Rheum 52 2005 608 611
217. I. Kone-Paut, E. Sanchez, A. Le Quellec, R. Manna, and I. Touitou Autoinflammatory gene mutations in Behçet's disease Ann Rheum Dis 66 2007 832 834
218. N. Barahmani, M. de Andrade, J. Slusser, Q. Zhang, and M. Duvic Interleukin-1 receptor antagonist allele 2 and familial alopecia areata J Invest Dermatol 118 2002 335 337
219. R. Tazi-Ahnini, A. Cox, A.J. McDonagh, M.J. Nicklin, F.S. di Giovine, and J.M. Timms Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interaction Eur J Immunogenet 29 2002 25 30
220. Y. Jin, C.M. Mailloux, K. Gowan, S.L. Riccardi, G. LaBerge, and D.C. Bennett NALP1 in vitiligo-associated multiple autoimmune disease N Engl J Med 356 2007 1216 1225
221. J.A. Simon, and R. Burgos-Vargas Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab Dermatology 216 2008 234 235
222. D. Rigopoulos, S. Gregoriou, G. Larios, E. Moustou, E. Belayeva-Karatza, and D. Kalogeromitros Etanercept in the treatment of vitiligo Dermatology 215 2007 84 85
223. C. Gabay, N. Cakir, F. Moral, P. Roux-Lombard, O. Meyer, and J.M. Dayer Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity J Rheumatol 24 1997 303 308
224. F. Tjernstrom, G. Hellmer, O. Nived, L. Truedsson, and G. Sturfelt Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17, DQ2) in determining susceptibility to systemic lupus erythematosus Lupus 8 1999 103 108
225. C.G. Parks, G.S. Cooper, M.A. Dooley, E.L. Treadwell, E.W. St Clair, and G.S. Gilkeson Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population-based study in the southeastern United States Ann Rheum Dis 63 2004 91 94
226. L.J. Tsai, J.L. Lan, C.Y. Lin, S.H. Hsiao, L.M. Tsai, and J.J. Tsai The different expression patterns of interleukin-1 receptor antagonist in systemic lupus erythematosus Tissue Antigens 68 2006 493 501
227. B. Brugos, E. Kiss, C. Dul, W. Gubisch, G. Szegedi, and S. Sipka Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease Hum Immunol 71 2010 874 877
228. A. Pontillo, M. Girardelli, A.J. Kamada, J.A. Pancotto, E.A. Donadi, and S. Crovella Polymorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus Autoimmunity 45 2012 271 278
229. F. Moosig, R. Zeuner, C. Renk, and J.O. Schroder IL-1RA in refractory systemic lupus erythematosus Lupus 13 2004 605 606